BACKGROUND: Nucleophosmin 1 (NPM1) is a nucleocytoplasmic shuttling protein mainly localized in the nucleolus. NPM1 is frequently mutated in acute myeloid leukemia (AML). NPM1c oligomerizes with wild-type nucleophosmin 1 (wt-NPM1), and this leads to its continuous cytoplasmic delocalization and contributes to leukemogenesis. Recent studies have shown that Cytoplasmic NPM1 (NPM1c) degradation leads to growth arrest and apoptosis of NPM1c AML cells and corrects wt-NPM1 normal nucleolar localization. METHODS: AML cells expressing wt-NPM1 or NPM1c or transfected with wt-NPM1 or NPM1c as well as wt-NPM1 and NPM1c AML xenograft mice were used. Cell growth was assessed with trypan blue or a CellTiter 96 proliferation kit. The cell cycle was studied with a propidium iodide (PI) assay. Caspase-mediated intrinsic apoptosis was assessed with annexin V/PI, the mitochondrial membrane potential, and poly(adenosine diphosphate ribose) polymerase cleavage. The expression of NPM1, p53, phosphorylated p53, and p21 was analyzed via immunoblotting. Localization was performed with confocal microscopy. The leukemia burden was evaluated by flow cytometry with an anti-human CD45 antibody. RESULTS: The imidazoquinoxaline 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503) induced selective proteasome-mediated degradation of NPM1c, restored wt-NPM1 nucleolar localization in NPM1c AML cells, and thus yielded selective growth arrest and apoptosis. Introducing NPM1c to cells normally harboring wt-NPM1 sensitized them to EAPB0503 and led to their growth arrest. Moreover, EAPB0503 selectively reduced the leukemia burden in NPM1c AML xenograft mice. CONCLUSIONS: These findings further reinforce the idea of targeting the NPM1c oncoprotein to eradicate leukemic cells and warrant a broader preclinical evaluation and then a clinical evaluation of this promising drug. 
INTRODUCTION
Acute myeloid leukemia (AML) is a complex, heterogeneous blood malignancy in which a failure to differentiate and an overproliferation of undifferentiated myeloid precursors result in impaired hematopoiesis and bone marrow (BM) failure. AML is associated with a highly variable prognosis and a high mortality rate, with overall survival exceeding 2 years for only 20% of elderly patients and 5 years for less than 50% of adult patients. 1 The prognosis of AML is mostly dependent on somatic genetic alterations used to classify the risk as favorable, intermediate, or unfavorable. 2 In AML patients with a normal karyotype, the most important genetic mutations influencing both the prognosis and the treatment strategies are mutations in nucleophosmin 1 (NPM1) and FMS-like tyrosine kinase 3 (FLT-3) internal tandem duplication. 3 Recently, more heterogeneous genomic categories for AML have been reported. 4 NPM1 is an essential gene 5 encoding a phosphoprotein 6 continuously shuttling between the nucleus, nucleolus, and cytoplasm but mainly residing in the nucleolus. 7, 8 NPM1 has many functions, including p14
Arf stabilization, ribosomal biogenesis regulation, centrosomal duplication control, and p53 activation in response to stress stimuli. 5, 6, 9 In AML, NPM1 mutations account for approximately one-third of patients, and this makes it one of the most frequently mutated genes. 6, 10 These mutations lead to the creation of a de novo nuclear export signal, 6, 10, 11 which results in cytoplasmic accumulation of NPM1c, along with wild-type nucleophosmin 1 (wt-NPM1) and thus leukemogenesis in these AML patients. 10 Despite all the advances in genetic and epigenetic changes in AML, there is still little progress in the treatment of the disease. Although complete remission is reached by almost 70% of patients with standard induction chemotherapy, refractory disease is common, and relapse represents the major cause of treatment failure. 12 Stem cell transplantation remains the best chance for long-term survival but is associated with several complications. 13 Therefore, new therapeutic approaches, specifically ones directly targeting the products of AML genetic alterations, are needed.
In NPM1c AML, degradation of the NPM1c oncoprotein leads to leukemic cell growth arrest and apoptosis. [14] [15] [16] We and others have recently shown that arsenic trioxide and retinoic acid selectively induce NPM1c proteasomal degradation and thus lead to apoptosis in NPM1c AML cells. 15, 16 This combined treatment restores NPM1 nucleolar localization ex vivo and in vivo. However, although the clearance of AML blasts was observed in a few treated patients, no cure was achieved, likely because of the complexity and status of the disease burden. This underlies the need for novel therapies to improve treatment outcomes.
Imiquimod is a toll-like receptor 7 immunomodulator 17, 18 used to treat certain skin cancers 19 and genital warts. 20 Imiquimod analogues, called imidazoquinoxalines, have been synthesized 21 ; among them, 1-(2-phenylethyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0203) and 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503) have been reported with promising antitumor activity. 22, 23 Indeed, EAPB0203 displayed pronouncedly higher in vitro potency against melanoma and adult T-cell leukemia cells in comparison with imiquimod. 23, 24 Later, EAPB0503 showed 10-fold higher cytotoxicity than EAPB0203 against melanoma cells. 25 More recently, EAPB0503
showed a potent apoptotic effect in chronic myeloid leukemia cells through BCR-ABL degradation. 26 Here we demonstrate that EAPB0503 induces NPM1c proteasomal degradation selectively in NPM1c AML cells and leads to their apoptosis. Importantly, introducing NPM1c to wt-NPM1-harboring cells sensitizes them to EAPB0503. Moreover, EAPB0503 treatment restores wt-NPM1 nucleolar localization in vitro and also in ex vivo treated blasts and selectively reduces the leukemia burden in NPM1c AML xenograft mice. These findings expand the antileukemic use of EAPB0503, reinforce the idea of targeting oncoprotein degradation to kill leukemic cells, and warrant a broader preclinical evaluation and then a clinical evaluation of this promising drug.
MATERIALS AND METHODS

Cell Lines
KG-1a, ML-2, and THP-1 cell lines (from F. Mazurier) and IMS-M2 (from H. de Th e) were grown in Roswell Park Memorial Institute 1640 medium. OCI-AML3 cells (from D. Bouscary) were grown in minimum essential medium a. Cells were seeded at a concentration of 2 3 10 5 /mL. EAPB0203 or EAPB0503 was used at 0.1 to 5 lM, the caspase inhibitor Z-Val-Ala-DL-Asp(OMe)-fluoromethylketone (zVAD) (Bachem Bioscience) was used at 50 mM, and the proteasome inhibitor PS-341 was used at 10 nM. 15 Cell growth was assessed with trypan blue or a CellTiter 96 proliferation kit (Promega).
Primary AML cells from patients' BM were extracted as described by El Hajj et al 15 after approval by the institutional review board at the American University of Beirut and after the patients had consented according to the Declaration of Helsinki.
Drugs
The synthesis of EAPB0203 and EAPB0503 was performed as described by Deleuze-Masquefa et al. 21, 22 Further optimization of EAPB0503 synthesis was achieved with microwave-assisted chemistry. 27 
Generation of Cells Expressing wt-NPM1 or NPM1c
Green fluorescent protein (GFP) wt-NPM1 or NPM1c inserts were amplified and ligated into a pBybe lentiviral vector by the EcoRI site. Stable OCI-AML2 expressing wt-NPM1 or NPM1c was generated by lentiviral transduction followed by blasticidin selection. GFP-positive cells were sorted with the FACSAria Special Order Research Product (Becton Dickinson) and grown in minimum essential medium a before the cell growth assessment. HeLa cells were transfected with pcDNA hemagglutinin (HA) expressing wt-NPM1 or NPM1c (from G. Tell) 28 with Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations and were grown in Dulbecco's modified Eagle's medium.
Xenograft Animal Studies
NOD/Shi-scid IL2rc 2/2 (NSG) mice were obtained from Jackson Laboratories (United States). Mouse protocols were approved by the institutional animal care and utilization committee of the American University of Beirut. OCI-AML3 or THP-1 cells (1 3 10 6 ) were injected into the tail vein of 8-week-old females (5 mice per group). On day 5 after the AML injection, the mice were treated with EAPB0503 (15 mg/kg) for 5 days a week over a period of 2 weeks. EAPB0503 was dissolved in dimethyl sulfoxide and diluted in an equal volume of lipofundin (vehicle) before its intraperitoneal administration to the mice. 24, 29 Flow Cytometry
Cell cycle analysis
Propidium iodide (PI) staining was used to assess the cell cycle as described by El Hajj et al. 15 
Annexin V staining
An annexin V-fluorescein isothiocyanate kit (BD Pharmingen) was used to assess phosphatidylserine exposure. Cells were treated with 1 lM EAPB0503 for 24 hours before annexin V/PI labeling and flow cytometry analysis.
Mitochondrial membrane potential (MMP)
The MMP was assessed by a cell's ability to retain rhodamine 123 (Sigma-Aldrich), as described by Saliba et al. 26 A Becton Dickinson FACS instrument was used; 10,000 events per condition were acquired, and FlowJo software (FlowJo LLC) was used for the analysis of the results.
Human CD45 staining
BM from the femurs and tibias of euthanized animals was flushed at the end of week 3 after AML inoculation. Cell surface staining was performed on 100 lL of a sample with 20 lL of an anti-human CD45 Peridinin Chlorophyll Protein (PerCP) conjugated antibody (345809; Becton Dickinson). After incubation for 15 minutes in the dark, erythrocytes were lysed with 1 mL of an FACS lysis solution (Becton Dickinson). Labeled samples were washed twice and analyzed on a Guava flow cytometer.
Immunoblot Analysis
After 48 hours of treatment with EAPB0203 or EAPB0503, proteins were probed with poly(adenosine diphosphate ribose) polymerase (PARP), p53, p21, HA (Santa Cruz), phosphorylated p53 (Biolabs), or NPM1 (Abcam) before incubation with the monoclonal horseradish peroxidase-conjugated secondary antibodies. The loading control was performed via probing with the mouse horseradish peroxidase-conjugated glyceraldehyde 3-phosphate dehydrogenase antibody (Abnova) or b-actin (Abcam). Immunoblots were detected with a luminol detection kit (Santa Cruz), and images were captured with the X-OMAT or BioRad ChemiDoc MP system.
Immunofluorescence Microscopy
AML cells or patients' blasts were spun down onto glass slides, fixed, and permeabilized with ice-cold methanol for 30 minutes. Immunostaining was performed with a monoclonal antibody against anti-B23 NPM1 (Santa Cruz) and a polyclonal antibody against the nucleolar marker fibrillarin (Abcam). Primary antibodies were revealed by Alexa Fluor 488-or Fluor 594-labeled secondary antibodies (Santa Cruz). Images were acquired with a Zeiss LSM 710 laser scanning microscope operated with Zen 2009 software (Carl Zeiss).
Statistical Analysis
Data are reported as averages and standard deviations. Statistical analyses were performed with the Student t test; a P value less than .05 was considered significant.
RESULTS
EAPB0203 and EAPB0503 Induce Growth Arrest in NPM1c AML Cells
We used 3 wt-NPM1 cell lines (THP-1, KG-1a, and MOLM-13) and the 2 available NPM1c AML cell lines (OCI-AML3 and IMS-M2) to test for EAPB0203 and EAPB0503 effects on cell growth and viability. We tested a range of drug concentrations (0.1-5 mM) and assessed cell growth for 5 days after treatment. Both treatments resulted in pronounced time-dependent growth inhibition of OCI-AML3 cells (Fig. 1A,B ). EAPB0203 at 5 mM resulted in significant OCI-AML3 growth inhibition (P < .05), which started 72 hours after treatment. Strikingly, EAPB0503 was more potent and at 0.1 mM resulted in significant growth inhibition, which started 96 hours after treatment (P < .001). Similarly significant results were obtained for both OCI-AML3 and IMS-M2: a concentration of 0.5 mM induced growth inhibition starting 72 hours after treatment (P < .001), and concentrations Original Article of 1 and 5 mM induced the same inhibitory effect 24 hours after treatment (P < .05 and P < .001, respectively; Fig.  1B ). Importantly, a median inhibitory concentration of 1 mM in OCI-AML3 and IMS-M2 cells was achieved 2 days after treatment with EAPB0503 (P < .05 and P < .001, respectively), whereas a concentration of 5 mM was achieved after treatment with EAPB0203 in OCI-AML3 (Fig. 1A,B) . This more potent effect of EAPB0503 versus EAPB0203 is in line with previously reported results. 26 THP-1 and KG-1a cells were minimally sensitive to the compounds, with only approximately 20% growth inhibition even 5 days after treatment (Fig. 1A,B) . MOLM-13 cells were also minimally sensitive to EAPB0203 but displayed approximately 50% growth inhibition 72 hours after treatment with EAPB0503 (Fig.  1A,B) . This percentage did not become more pronounced even 5 days after treatment, and the only significant result was obtained with concentrations of 1 and 5 mM, 120 and 72 hours after treatment, respectively (P < .05; Fig. 1B ).
Introduction of NPM1c Into wt-NPM1-Expressing Cells Sensitizes Them to EAPB0503
To examine whether the growth inhibition solely observed in NPM1c cell lines was due to NPM1 mutations, we introduced NPM1c to wt-NPM1-expressing cells and checked for their sensitivity to EAPB0503. We used the wt-NPM1-expressing AML cell line (OCI-AML2) and generated by lentiviral transduction and then blasticidin selection cells stably expressing either GFP-tagged wt-NPM1 or NPM1c. GFP-positive cells were sorted, and a range of EAPB0503 concentrations (0.1-5 mM) were tested to assess cell growth more than 5 days after treatment. Interestingly, stable expression of NPM1c in OCI-AML2 resulted in significantly pronounced growth inhibition at 0.1 mM that started 72 hours after treatment and at 0.5, 1, and 5 mM that started 48 hours after treatment (P < .05; Fig. 1C) . A minimal effect was observed in wt-NPM1 OCI-AML2: maximum growth inhibition of 30% (nonsignificant) was obtained 48 hours after treatment with concentrations of 0.5, 1, and 5 mM (Fig. 1C) . Similar results were obtained with HeLa cells: a concentration of 1 mM induced growth arrest starting 48 hours after treatment in HA NPM1c-transfected cells (P < .001) but not wt-NPM1-transfected cells (Fig. 1D ). This growth inhibition was reversed upon the addition of PS-341 only in NPM1c-expressing cells both 24 and 48 hours after treatment (P < .05; Fig. 1D ). Our results strongly suggest that introducing NPM1c into cells harboring wt-NPM1 sensitizes them to EAPB0503. Because of its potency, especially in NPM1c AML cells, only EAPB0503 was adopted at its median inhibitory concentration of 1 mM for the remainder of the study.
EAPB0503 Induces Massive Apoptosis in NPM1c AML Cells
To examine the mechanisms dictating growth inhibition and cell death, a cell cycle analysis was performed 48 hours after treatment with 1 mM EAPB0503. A sharp increase in the pre-G 0 cell percentage, which reached more than 80%, was obtained upon the treatment of OCI-AML3 with EAPB0503. Minimal effect was observed in the wt-NPM1 cells (THP-1, KG-1a, and MOLM-13; Fig. 2A and Supporting Fig. 1A [see online supporting information]). The cell cycle distribution showed no major variation in all the tested AML cells untreated or treated with EAPB0503 ( Fig. 2B and Supporting Fig. 1A [see online supporting information]), and this shows that the drug is mostly inducing pre-G 0 accumulation in NPM1c AML without affecting the other cell cycle phases.
To confirm the apoptosis, annexin V/PI labeling was performed, and a significant increase of 40% in annexin V positivity was observed only in OCI-AML3 cells treated with 1 mM EAPB0503 for 24 hours (P < .005; Fig. 2C The intrinsic apoptotic cascade is characterized by many steps, the earliest of which is the disruption of the MMP. 30 Because EAPB0503 induces apoptosis in NPM1c AML cells, we measured MMP in untreated cells or 2 days after treatment with EAPB0503. Treated OCI-AML3 cells failed to retain the rhodamine 123 dye inside their mitochondria (Fig. 2D and Supporting Fig. 1C [see online supporting information]). Conversely, all wt-NPM1 AML cells showed no loss of MMP up to 48 hours after treatment (Fig. 2D and Supporting Fig. 1C [see online supporting information]).
To study the effect of MMP dissipation in EAPB0503-treated AML cells on the caspase cascade, we examined PARP cleavage. The treatment of OCI-AML3 for 48 hours with EAPB0503 but not with EAPB0203 led to PARP cleavage into its death-associated fragment (Fig.  2E) ; this occurred to a much lesser extent in the wt-NPM1 AML cells treated with either drug (Fig. 2E) . Interestingly, the cotreatment of cells with the general caspase inhibitor zVAD and EAPB0503 reversed EAPB0503 growthinduced inhibition in OCI-AML3 (Fig. 2F) , whereas no effect was observed in wt-NPM1 cells (THP-1 and MOLM-13; Fig. 2F ). Altogether, our results indicate that the selective growth arrest obtained in NPM1c AML with EAP0503 involves caspase activation.
EAPB0503 Treatment Activates p53 Signaling in NPM1c AML Cells
To determine whether the EAPB0503-associated growth inhibition and apoptosis were p53-mediated, p53 protein levels were monitored 48 hours after treatment with 1 mM EAPB0203 or EAPB0503, and the results were compared with untreated controls. EAPB0503 induced substantial upregulation of total p53 protein levels and the p53 phosphorylated form exclusively in the NPM1c OCI-AML3 cell line (Fig. 2G) , whereas no effect was observed upon the treatment of these cells with EAPB0203 (Fig. 2G) . Accordingly, p21 protein levels were upregulated only in EAPB0503-treated OCI-AML3 (Fig. 2G) . Because p53 is mutated in both THP-1 and KG-1a cell lines, 31 we tested p53 only in the wt-NPM1 MOLM-13 cell line and found that p53, phosphorylated p53, and p21 protein levels remained unchanged upon treatment with either drug (Fig.  2G) . Altogether, these results show that EAPB0503 is a potent inducer of apoptosis exclusively in NPM1c AML cells.
Original Article
EAPB0503 Induces NPM1c Proteasomal Degradation and Restores wt-NPM1 Nucleolar Localization in NPM1c AML Cells
Given the selective activity of EAPB0503 in NPM1c AML cells, we examined its effect on NPM1c oncoprotein degradation. Although no effect of EAPB0203 or EAPB0503 on NPM1 expression was obtained in THP-1, MOLM-13, or KG-1a cells (Fig. 3A) , EAPB0503 but not EAPB0203 triggered NPM1 downregulation in OCI-AML3 cells (Fig. 3B) , and this suggests that NPM1c is the primary target of EAPB0503. Critically, adding the proteasome inhibitor PS-341 reversed both NPM1 downregulation and growth arrest (Fig. 3C ) specifically in OCI-AML3 (Supporting Fig. 2 [see online supporting information]). To eliminate any potential off-target effect of the treatment, we treated HA-tagged, wt-NPM1-or NPM1c-transfected HeLa cells with EAP0503 alone or in combination with PS-341. With an anti-HA antibody, our results showed that EAPB0503 proteasome-mediated degradation was selective for NPM1c and was reversed upon the addition of PS-341 (Fig. 3D) . Using primers specific for either wt-NPM1 or NPM1c messenger RNA, we found that neither transcript level was affected in EAPB0503-treated cells (Supporting Fig. 3 [see online supporting information]), and this shows that NPM1 downregulation occurs at the protein level. Collectively, these results strongly suggest that EAPB0503-treated NPM1c AML cells are secondary to oncoprotein degradation.
In NPM1c AML, wt-NPM1 oligomerized with NPM1c and was delocalized to the cytoplasm (Fig.  3E) , 6, 10, 11 whereas the treatment of THP-1 cells with EAPB0503 did not affect NPM1 nucleolar localization (Fig. 3E) , EAPB0503 treatment of OCI-AML3 restored the nucleolar localization of the remaining NPM1 protein (Fig. 3E) . This suggests that EAPB0503-triggered degradation of NPM1c releases wt-NPM1 and thus corrects the nucleolar organization defect.
EAPB0503 Selectively Inhibits Proliferation, Induces NPM1c Degradation, and Restores wt-NPM1 Nucleolar Localization in Ex Vivo Treated NPM1c AML Blasts
Primary blasts derived from the BM of 6 AML patients were treated with EAPB0503. Patient 1 had acute promyelocytic leukemia with PML/RARA rearrangement, patients 2 and 6 were AML patients with wt-NPM1, and patients 3 to 5 harbored an NPM1 mutation without FLT-3 internal tandem duplication. Although leukemic cells derived from patients 1, 2, and 6 were not sensitive to EAPB0503 treatment, those derived from patients 3 to 5 were highly sensitive, and almost all died within the first 48 hours after treatment (Fig. 4A) . Moreover, EAPB0503 induced NPM1c selective degradation in patients 3 to 5 (Fig. 4B) and restored the wt-NPM1 nucleolar localization only in those patients (Fig. 4C) . Collectively, EAPB0503 exerts its growth-inhibition effect, induces NPM1c degradation, and corrects the wt-NPM1 nucleolar localization selectively in treated NPM1c AML blasts ex vivo.
EAPB0503 Selectively Reduces the Leukemia BM Burden in OCI-AML3 Xenograft Mice
Several xenograft mouse models have been generated. 32, 33 Furthermore, OCI-AML3 and THP-1 cells are known to express the hCD45 marker. 33, 34 To assess the in vivo efficacy of EAPB0503, we injected NSG mice with OCI-AML3 or THP-1 cells. Five days after the AML cell injection, xenograft mice were treated intraperitoneally with EAPB0503 or its respective vehicle (dimethyl sulfoxide/lipofundin) once daily for 5 consecutive days a week over a period of 2 weeks. At the end of week 3 after the AML cell inoculation, BM was flushed from the femurs and tibias of untreated mice and vehicle-or EAPB0503-treated mice. Human AML xenograft cells were stained with the human-specific hCD45 1 antibody and analyzed with flow cytometry. Our results show that the OCI-AML3 BM burden was markedly reduced from 34% to 10% upon EAPB0503 treatment (P < .05; Fig. 5A,B) , whereas the THP-1 burden was not affected (22% for untreated mice vs 23% for EAPB0503-treated mice; Fig. 5B,C) . These results indicate that EAPB0503 is a promising drug that selectively reduces the NPM1c AML BM burden in xenograft animals and warrants more preclinical investigation and then a clinical investigation.
DISCUSSION
In this report, we examine the effects of EAPB0503 and EAPB0203, 2 imidazoquinoxaline agents, on AML cell Figure 4 . EAPB0503 inhibits proliferation, induces the degradation of NPM1c, and restores the nucleolar localization of wt-NPM1 selectively in ex vivo treated blasts derived from NPM1c AML patients. Primary leukemic blasts were harvested from 3 patients and treated with 1 mM EAPB0503. Patient 1 had APL with PML/RARA rearrangement, patients 2 and 6 were AML patients with wt-NPM1, and patients 3 to 5 were AML patients harboring an NPM1 mutation without FLT-3 internal tandem duplication. (A) Proliferation of AML blasts after treatment for 24, 48, and 72 hours. Cell growth is represented as the percentage of the control. (B) Western blot analysis for NPM1 (wt1c) and GAPDH in treated AML blasts as indicated previously. (C) Confocal microscopy of derived blasts from patients 2 and 3. NPM1 (wt1c) was stained with an anti-NPM1 (wt1c) antibody (green), nucleoli were stained with anti-fibrillarin (red), and nuclei were stained with 4,6-diamidino-2-phenylindole (blue). Images represent z-sections. AML indicates acute myeloid leukemia; APL, acute promyelocytic leukemia; EAPB0503, 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine; FLT-3, FMS-like tyrosine kinase 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NPM1, nucleophosmin 1; wt-NPM1, wild-type nucleophosmin 1; NPM1c, cytoplasmic NPM1; NPM1 (wt+c), wild-type and cytoplasmic NPM1.
lines. Imidazoquinoxalines have arisen as promising anticancer drugs on the basis of their in vitro activity in T-cell leukemia and chronic myeloid leukemia and their in vivo activity in melanoma. 22, 23, 26 We show that EAPB0503 has a specific growth-inhibition effect on NPM1c OCI-AML3 and IMS-M2 cells in a dose-and timedependent manner. EAPB0503 activity in OCI-AML3 cells is considerably more pronounced than EAPB0203 ; PerCP: peridinin chlorophyll protein (*P <.05, **P <.01, ***P <.001); SSC, side scatter. activity, and this in line with its higher antitumor potency in other cancer types. 24, 25 Introducing NPM1c into cells harboring wt-NPM1 sensitizes them to EAPB0503. The phenyl group is directly linked to the core imidazoquinoxaline heterocycle in EAPB0503, whereas an ethyl link exists in EAPB0203 between the 2 parts. This ethyl linker in EAPB0203 appears to abolish the antileukemic activity in most of the tested leukemia models in comparison with the direct linkage in the EAPB0503 compound. 26 Indeed, this change in the EAPB0503 structure enhanced its in vitro activity and led to better bioavailability in rats. 29 We have shown that EAPB0503 induces growth arrest and apoptosis in NPM1c AML cells. Apoptosis is accompanied by the dissipation of MMP and PARP cleavage, and this strongly suggests the involvement of the intrinsic apoptotic pathway. Our results are consistent with previous studies showing antitumor activity of EAPB0503 in melanoma and chronic myeloid leukemia with a mode of action similar to the mode of this compound.
23,26
NPM1c characterizes one-third of AML patients, 6, 10 and when it alone is present in the case of a normal karyotype, it confers a better prognosis. 35 NPM1 mutations mediate malignancies as observed in transgenic and knock-in mice. 36 Mutated NPM1 is the key hallmark of OCI-AML3 and IMS-M2 cells for maintaining their malignant proliferation. In NPM1c AML, emerging studies have shown that therapies targeting NPM1c oncoprotein degradation lead to inhibition of proliferation and the cell death of leukemic cells. [14] [15] [16] In line with these findings, we have demonstrated that EAPB0503 degrades the NPM1c oncoprotein in a proteasome-dependent manner. This results in correcting the wt-NPM1 nucleolar localization in both NPM1c AML cells and ex vivo treated blasts derived from NPM1c AML patients. Furthermore, in in vivo NPM1c AML xenograft animals, EAPB0503 showed a selective reduction of the BM leukemia burden.
Recently, EAPB0503 was shown to exert potent inhibition of tubulin polymerization that correlated with its antiproliferative activity. 27 Therefore, the corrective effect of wt-NPM1 nucleolar localization after NPM1c degradation warrants testing the disruption of the microtubule network in NPM1c AML cells to further explain the mechanism of cell death.
Nowadays, most AML patients are still dying, especially because the basic therapies have remained unchanged or have only slightly changed over the last 2 decades. Nonetheless, before novel clinical therapies are introduced, a deep understanding of the therapeutic approach is required. The evolutionary changes emerging in AML classification based on the morphology and cytogenetic/genetic changes reflect the importance of identifying the subtype-specific biology to determine the appropriate targeted therapy triggering degradation of the byproducts of these genetic modifications. 13 Our results suggest that EAPB0503 holds promise for the treatment of NPM1c AML, especially in those patients with mutation A, 37 which represents 80% of NPM1 mutations in AML 38 and is the hallmark mutation present in OCI-AML3 and IMS-M2. 39 These promising results were translated in vivo: among treated mice, EAPB0503 decreased the BM leukemia burden only in NPM1c xenograft mice. Further in vivo studies (survival and organ infiltration) and ex vivo studies (treated blasts) are required for us to have a complete idea of EAPB0503's mechanism of action. 
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